Business Description
West Pharmaceutical Services Inc
NAICS : 339112
SIC : 3841
ISIN : US9553061055
Total Employee Number:
10,800Compare
Compare
Traded in other countries / regions
WST.USAWPS.GermanyW2ST34.Brazil1WST.ItalyWST.Mexico IPO Date
2021-02-26Description
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.65 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.37 | |||||
Interest Coverage | 344.8 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 16.47 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.5 | |||||
3-Year EBITDA Growth Rate | -0.1 | |||||
3-Year EPS without NRI Growth Rate | -5.3 | |||||
3-Year FCF Growth Rate | 3.6 | |||||
3-Year Book Growth Rate | 6.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.07 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 100 | |||||
14-Day RSI | 99.99 | |||||
12-1 Month Momentum % | 18.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.71 | |||||
Quick Ratio | 2.04 | |||||
Cash Ratio | 0.77 | |||||
Days Inventory | 76.26 | |||||
Days Sales Outstanding | 68.24 | |||||
Days Payable | 43.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.11 | |||||
3-Year Dividend Growth Rate | 5.2 | |||||
3-Year Average Share Buyback Ratio | 0.9 | |||||
Shareholder Yield % | 1.44 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 36.28 | |||||
Operating Margin % | 21.41 | |||||
Net Margin % | 16.85 | |||||
EBITDA Margin % | 26.36 | |||||
FCF Margin % | 14.26 | |||||
OCF Margin % | 22.28 | |||||
ROE % | 18.3 | |||||
ROA % | 13.53 | |||||
ROIC % | 17.92 | |||||
3-Year ROIIC % | -19.72 | |||||
ROC (Joel Greenblatt) % | 28.07 | |||||
ROCE % | 19.82 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 46.91 | |||||
Forward PE Ratio | 34.17 | |||||
PE Ratio without NRI | 44.02 | |||||
Shiller PE Ratio | 55.08 | |||||
Price-to-Owner-Earnings | 59.6 | |||||
PEG Ratio | 8.15 | |||||
PS Ratio | 7.9 | |||||
PB Ratio | 8.32 | |||||
Price-to-Tangible-Book | 8.65 | |||||
Price-to-Free-Cash-Flow | 55.61 | |||||
Price-to-Operating-Cash-Flow | 35.6 | |||||
EV-to-EBIT | 36.55 | |||||
EV-to-Forward-EBIT | 26.96 | |||||
EV-to-EBITDA | 28.95 | |||||
EV-to-Forward-EBITDA | 21.2 | |||||
EV-to-Revenue | 7.63 | |||||
EV-to-Forward-Revenue | 5.41 | |||||
EV-to-FCF | 53.67 | |||||
Price-to-GF-Value | 0.97 | |||||
Price-to-Projected-FCF | 3.94 | |||||
Price-to-DCF (Earnings Based) | 1.32 | |||||
Price-to-DCF (FCF Based) | 1.41 | |||||
Price-to-Median-PS-Value | 1.21 | |||||
Price-to-Graham-Number | 4.12 | |||||
| Price-to-Net-Current-Asset-Value | 35.15 | |||||
Earnings Yield (Greenblatt) % | 2.74 | |||||
FCF Yield % | 1.85 | |||||
Forward Rate of Return (Yacktman) % | 2.4 |
West Pharmaceutical Services Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
West Pharmaceutical Services Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-23 08:00 | In 117 days | ||
| Third quarter earnings results for 2026 | 2026-10-23 | In 116 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 08:00 | In 26 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 25 days | ||
| William Blair Annual Growth Stock Conference | 2026-06-02 16:00 | 5,112.51 (+0.00%) | ||
| Bank of America Global Healthcare Conference | 2026-05-20 14:20 | 5,112.51 (+0.00%) | ||
| General meeting for 2026 | 2026-05-04 09:30 | 5,112.51 (+0.00%) | ||
| USD 0.220000 Cash Dividend | 2026-04-29 | 5,112.51 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 08:00 | 5,112.51 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 5,112.51 (+0.00%) |
Show
Entries
Press Release
Articles on West Pharmaceutical Services Inc
No articles.